Ozomet-PG 2 Tablet ER

Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin resistance in adipose tissue, muscle, and the liver. The combination therapy targets multiple pathophysiological defects in type 2 diabetes, offering improved glycemic control compared to monotherapy. Ozomet-PG 2 Tablet ER is indicated for patients inadequately controlled on diet and exercise alone or on monotherapy, and it may be used as an adjunct to insulin therapy.

The extended-release formulation allows for once-daily dosing, enhancing patient compliance. Use of this medication requires monitoring of blood glucose levels, liver function, and potential adverse effects such as hypoglycemia, gastrointestinal disturbances, weight gain, and fluid retention. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and heart failure.